Seattle Genetics has invested widely in research and innovation meant to fight the cancer pandemic and their recent plans could further this resolve. Their fast growth can be attributed to the several drug pipelines they have offered to the market coupled with the inclusion of leading pharmaceutical companies in their research and production processes.
The company has is investing to widen its pipeline and is working to see that its first drug is adopted for use. They are planning to come up with new and more advanced drugs and cancer treatment methods as well as enlarging their employee base. This move to inject more effort into research meant to unveil drugs for treatment of cancer underscores their role as a research center concerned about offering solutions.
Adcetris, one of the many drugs Seattle Genetics has produced, is largely applied in the treatment of lymphomas and the drug alone raked in at least $226 million from sales in the United States and Canada and they are optimistic this amount may rise to more than $255 million before the end of 2016.
Seattle Genetics is planning to introduce another drug, 33A, into the third phase of the clinical trials in 2016. The drug will be used in the treatment of acute myeloid leukemia. Additionally, they are manufacturing a drug that is used in the treatment of breast cancer and two others for bladder cancer. Clay Siegall, the CEO and President of the company explained that they are going to put a huge amount of data in the three drugs for the year 2016. This process will be made successful through the hiring of additional 100 employees.
Clay B. Siegall, Ph.D, CEO, Seattle Genetics
Clay Seagall is the founder and CEO of Seattle Genetics. He also works as the President of the company since its establishment in 1998. He is trained as a scientist with focus on cancer therapies, something that guided him to build Seattle Genetics on a foundation of innovation and research. Through his effort, Seattle Genetics has partnered with multiple companies for its ADC technology, which include AbbVie, Pfizer and GlaxoSmithKline and Genetech.